{"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"17"}],"units":"Participants"}],"groups":[{"description":"MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles\n\nMK-3475","id":"BG000","title":"Treatment"},{"description":"MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study\n\nMK-3475\n\nCopanlisib","id":"BG001","title":"Combination"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"18","upperLimit":"88","value":"71"},{"groupId":"BG002","lowerLimit":"18","upperLimit":"88","value":"71"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"17"}],"units":"Participants"}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"9"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"8"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"17"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG002","value":"17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"17"}],"units":"Participants"}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Study did not progress to portion with combination of pembrolizumab and copanlisib"}